Welcome to the International Society for Vaccines
Dr. Ronald Ellis has >30 years of scientific, managerial and executive R&D experience for vaccines, immunotherapeutics and biological products in small, medium and large biotech / pharma companies. He has championed or led R&D efforts on a wide range of vaccines and Immunotherapeutics from discovery or in-licensure through development to product licensure and launch in major markets. These include several licensed vaccines – human papilloma virus and rotavirus for which he initiated these two vaccine programs at Merck, Haemophilus influenzae type b, hepatitis B and varicella – which together have annual sales ~$4B.
At Merck he led Vaccine Research as well as joint projects with partner companies for developing several combination vaccines. He had a succession of senior R&D positions, beginning with his start-up and position of Site Head of a large Boston-area vaccine development facility for BioChem Pharma that subsequently became part of Shire then ID Biomedical. He then worked at Avant Immunotherapeutics before joining NasVax, then FutuRx in 2014.
He has managed numerous functions in all aspects of vaccines and biologicals ranging from research to process and analytical development through to clinical and project management, as well as strategy and evaluation of new opportunities. He is (co)author of over 100 publications and over 35 review articles, and editor/coeditor of 8 books. He has made over 100 invited presentations, chaired many sessions at international scientific conferences, consulted for different companies, and served on many SABs.
He is the founding (2004) and Editor-in-Chief of the peer-reviewed indexed journal Human Vaccines & Immunotherapeutics.